ErbB2 is essential in the prevention of dilated cardiomyopathy

Amplification of the gene encoding the ErbB2 (Her2/neu) receptor tyrosine kinase is critical for the progression of several forms of breast cancer. In a large-scale clinical trial, treatment with Herceptin (trastuzumab), a humanized blocking antibody against ErbB2, led to marked improvement in survival. However, cardiomyopathy was uncovered as a mitigating side effect, thereby suggesting an important role for ErbB2 signaling as a modifier of human heart failure. To investigate the physiological role of ErbB2 signaling in the adult heart, we generated mice with a ventricular-restricted deletion of Erbb2. These ErbB2-deficient conditional mutant mice were viable and displayed no overt phenotype. However, physiological analysis revealed the onset of multiple independent parameters of dilated cardiomyopathy, including chamber dilation, wall thinning and decreased contractility. Additionally, cardiomyocytes isolated from these conditional mutants were more susceptible to anthracycline toxicity. ErbB2 signaling in cardiomyocytes is therefore essential for the prevention of dilated cardiomyopathy.

[1]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[2]  M. Hamada,et al.  Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats. , 1999, Clinical science.

[3]  Jens C. Brüning,et al.  Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression , 1999, Nature Genetics.

[4]  H. Dang,et al.  Effects of radiation on Ca2+ signaling in salivary epithelial cell lines transfected with Bcl-2 and Bcl-XL. , 2001, European journal of oral sciences.

[5]  J. Ross,et al.  Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Cho,et al.  Defective β-Adrenergic Receptor Signaling Precedes the Development of Dilated Cardiomyopathy in Transgenic Mice with Calsequestrin Overexpression* , 1999, The Journal of Biological Chemistry.

[7]  B. Lorell,et al.  Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. , 1999, Circulation.

[8]  M. V. Vander Heiden,et al.  Bcl-x l Promotes the Open Configuration of the Voltage-dependent Anion Channel and Metabolite Passage through the Outer Mitochondrial Membrane* , 2001, The Journal of Biological Chemistry.

[9]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[10]  C. J. Duncan,et al.  A model for Duchenne muscular dystrophy ? The action of cytochalasin B on mouse soleus muscle , 1994 .

[11]  K. Chien,et al.  High-efficiency, long-term cardiac expression of foreign genes in living mouse embryos and neonates. , 2000, Circulation.

[12]  T. Miyauchi,et al.  A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[13]  D. Riethmacher,et al.  The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. , 1998, Genes & development.

[14]  D. Opel,et al.  Neuregulins Promote Survival and Growth of Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[15]  J. Ross,et al.  Selective Requirement of Myosin Light Chain 2v in Embryonic Heart Function* , 1998, The Journal of Biological Chemistry.

[16]  Susan C. Brown,et al.  Utrophin-Dystrophin-Deficient Mice as a Model for Duchenne Muscular Dystrophy , 1997, Cell.

[17]  T. Bourgeron,et al.  Biochemical and molecular investigations in respiratory chain deficiencies. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[18]  R. Benjamin,et al.  Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy. , 1978, Cancer treatment reports.

[19]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[20]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[21]  M Rabinowitz,et al.  Biochemical Correlates of Cardiac Hypertrophy: I. Experimental Model; Changes in Heart Weight, RNA Content, and Nuclear RNA Polymerase Activity , 1968, Circulation research.

[22]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[23]  R. Dillman,et al.  Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. , 2000, Seminars in oncology.

[24]  J. Baselga.  Current and planned clinical trials with trastuzumab (Herceptin). , 2000, Seminars in oncology.

[25]  M. Martone,et al.  Chronic Phospholamban–Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy , 1999, Cell.

[26]  G. Frantz,et al.  ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. , 1997, Development.

[27]  P. Bunn,et al.  HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. , 2000, Seminars in oncology.

[28]  K. Chien,et al.  Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. , 1998, Development.

[29]  Minoru Hongo,et al.  MLP-Deficient Mice Exhibit a Disruption of Cardiac Cytoarchitectural Organization, Dilated Cardiomyopathy, and Heart Failure , 1997, Cell.

[30]  Ferrans Vj.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity. , 1978, Cancer treatment reports.

[31]  J. Sanes,et al.  Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy , 1997, Cell.

[32]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[33]  T. Koide,et al.  Biochemical correlates of cardiac hypertrophy. IV. Observations on the cellular organization of growth during myocardial hypertrophy in the rat. , 1969, Circulation research.

[34]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.

[35]  V. Ferrans.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity. , 1978, Cancer treatment reports.

[36]  J. Sparano.  Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. , 2001, Seminars in oncology.

[37]  R. Ozols,et al.  The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.

[38]  S. Izumo,et al.  Apoptosis: basic mechanisms and implications for cardiovascular disease. , 1998, Circulation research.

[39]  J. Ross,et al.  Transthoracic echocardiography in models of cardiac disease in the mouse. , 1996, Circulation.

[40]  K. Campbell,et al.  Disruption of the Sarcoglycan–Sarcospan Complex in Vascular Smooth Muscle A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy , 1999, Cell.